PON1 Antibody (453223)

Detection of Human/Mouse PON1 by Western Blot.

Western blot shows lysates of mouse liver tissue, human liver tissue and an enriched HDL/LDL fraction of human plasma obtained from ultracentrifugation. PVDF membrane was probed with 0.5 µg/mL of Human/Mouse PON1 Monoclonal Antibody (Catalog # MAB4926) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005). A specific band was detected for PON1 at approximately 43 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 2.

Detection of PON1 by Western Blot

Vutiglabridin protects against diet-induced obesity in hyperlipidemic mice. (A) LDLR−/− mice were utilized to investigate the role of vutiglabridin against diet-induced obesity and hyperlipidemia. Mice were fed four different diets for three weeks: Chow ± vutiglabridin or Western diet (WD) ± vutiglabridin. Dosing of vutiglabridin was at 100 mg/kg. Both male and female mice, between 8–12 weeks of age, with five mice per group were used. The mice were weighed prior to the start of the experiment. At the end of the third week of feeding, the experiment was terminated. (B) Changes in body weights were determined between the weight of the mice before the start of the experiment and final weights prior to termination. (C) Fat mass changes were assessed and quantified as percentage of final fat mass over total body weight × 100. (D) Muscle (lean) mass changes were assessed and quantified as percentage of final muscle mass over total body weight × 100. Plasma total cholesterol levels (E) were also determined. PON1 expression was evaluated at the end of the study in all groups via Western blot analysis, as reflected in the representative image (F). PON1 expression was normalized to transferrin and quantified as a ratio of PON1 to transferrin (G). The plasma paraoxonase activity as PON1 specific enzyme activity was measured in WD-fed groups (H). The data are represented as mean ± SEM. One-way ANOVA with Tukey’s multiple comparison test was performed. Student’s t-test was performed for (H). Statistically significant data are noted as * p < 0.05, ** p < 0.01, *** p < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37189434), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of PON1 by Western Blot

Role of vutiglabridin in modulating expression and activity of PON1. (A) Male and female WT, C57BL/6J mice between 8−10 weeks of age were pre-bled for plasma collection and were fed a chow diet for two weeks, followed by vutiglabridin at a dose of 100 mg/kg in their chow diet for another two weeks (n = 7–8/group), at which point the post-bleeding plasma collection occurred. Arylesterase (B) and lactonase (C) assays were performed on the plasma collected from the mice for comparison of pre- vs. post-vutiglabridin treatment (D). PON1 expression (n = 4/group) was evaluated in the plasma of male, WT mice via Western blot analysis, normalized to transferrin, and quantified as a ratio of PON1 to transferrin (E). The data are represented as mean ± SEM. Student’s t-test was performed. Statistically significant data are noted as ** p < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/37189434), licensed under a CC-BY license. Not internally tested by R&D Systems.